This company does its navel-gazing on the clock. Pluristem Therapeutics (formerly Pluristem Life Systems) employs a patented technology to artificially grow stromal stem cells and T-cells from umbilical cord blood, generating quantities sufficient to be used in cell therapies and bone marrow transplants. The company's PluriX Bioreactor system, a technological stem cell expansion platform that employs this stem cell growth, is being developed with the hope of producing and selling cell therapy products for ailments including degenerative, cardiovascular, and immune system disorders.